Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA GroupsSusana Vives, Pau Montesinos, David Quintela et al.|Cancers|2024Cited by 4
Ruxolitinib in Acute and Chronic Graft-Versus-Host Disease: Real Life Experience in a Multi-Centre StudyVirginia Escamilla Gómez, Josè Antonio Pérez-Simón, Lucía López‐Corral et al.|Blood|2022Cited by 2